After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...
Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...
Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.
Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.
Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor. DXCM’s stock fell nearly ...
Zacks Investment Research on MSN
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback